ACADIA Total Other Income Expense Net vs Selling And Marketing Expenses Analysis
ACAD Stock | USD 15.20 0.34 2.19% |
ACADIA Pharmaceuticals financial indicator trend analysis is way more than just evaluating ACADIA Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ACADIA Pharmaceuticals is a good investment. Please check the relationship between ACADIA Pharmaceuticals Total Other Income Expense Net and its Selling And Marketing Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.
Total Other Income Expense Net vs Selling And Marketing Expenses
Total Other Income Expense Net vs Selling And Marketing Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ACADIA Pharmaceuticals Total Other Income Expense Net account and Selling And Marketing Expenses. At this time, the significance of the direction appears to have pay attention.
The correlation between ACADIA Pharmaceuticals' Total Other Income Expense Net and Selling And Marketing Expenses is -0.77. Overlapping area represents the amount of variation of Total Other Income Expense Net that can explain the historical movement of Selling And Marketing Expenses in the same time period over historical financial statements of ACADIA Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ACADIA Pharmaceuticals' Total Other Income Expense Net and Selling And Marketing Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Other Income Expense Net of ACADIA Pharmaceuticals are associated (or correlated) with its Selling And Marketing Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling And Marketing Expenses has no effect on the direction of Total Other Income Expense Net i.e., ACADIA Pharmaceuticals' Total Other Income Expense Net and Selling And Marketing Expenses go up and down completely randomly.
Correlation Coefficient | -0.77 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Total Other Income Expense Net
Selling And Marketing Expenses
Most indicators from ACADIA Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ACADIA Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.At present, ACADIA Pharmaceuticals' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 1.8 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.51.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 465.0M | 507.1M | 680.7M | 714.7M | Total Revenue | 484.1M | 517.2M | 726.4M | 762.8M |
ACADIA Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
ACADIA Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ACADIA Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 783.2M | 782.6M | 700.1M | 587.8M | 749.0M | 786.4M | |
Total Stockholder Equity | 699.1M | 627.0M | 540.9M | 400.4M | 431.8M | 232.8M | |
Net Debt | (183.3M) | (281.6M) | (91.3M) | (52.8M) | (131.5M) | (124.9M) | |
Other Assets | 5.3M | 54.7M | 16.0M | 11.1M | 12.7M | 7.9M | |
Common Stock Shares Outstanding | 147.2M | 157.3M | 160.5M | 161.7M | 163.8M | 172.0M | |
Liabilities And Stockholders Equity | 783.2M | 782.6M | 700.1M | 587.8M | 749.0M | 786.4M | |
Non Current Liabilities Total | 9.2M | 49.6M | 63.2M | 61.8M | 62.9M | 66.1M | |
Other Stockholder Equity | 2.4B | 2.6B | 2.7B | 2.8B | 2.9B | 3.0B | |
Total Liab | 84.0M | 155.6M | 159.2M | 187.4M | 317.2M | 333.1M | |
Other Current Liab | 64.2M | 92.4M | 80.9M | 103.6M | 225.7M | 237.0M | |
Total Current Liabilities | 74.8M | 106.0M | 96.1M | 125.6M | 254.3M | 267.0M | |
Property Plant And Equipment Net | 12.7M | 56.4M | 66.3M | 61.6M | 56.5M | 59.3M | |
Retained Earnings | (1.7B) | (2.0B) | (2.2B) | (2.4B) | (2.4B) | (2.3B) | |
Accounts Payable | 7.2M | 8.5M | 6.9M | 12.7M | 17.5M | 18.4M | |
Cash | 189.7M | 326.0M | 147.4M | 114.8M | 188.7M | 198.1M | |
Non Current Assets Total | 22.9M | 65M | 82.3M | 79.9M | 132.8M | 139.5M | |
Non Currrent Assets Other | 7.6M | 7.4M | 6.6M | 5.3M | 5.1M | 2.6M | |
Cash And Short Term Investments | 697.4M | 632.0M | 520.7M | 416.8M | 438.9M | 269.3M | |
Short Term Investments | 507.7M | 305.9M | 373.3M | 302.0M | 250.2M | 185.1M | |
Other Current Assets | 18.6M | 25.7M | 23.9M | 21.4M | 39.1M | 41.0M | |
Property Plant And Equipment Gross | 12.7M | 56.4M | 66.3M | 61.6M | 66.0M | 69.3M | |
Total Current Assets | 760.3M | 717.6M | 617.8M | 507.9M | 616.1M | 646.9M | |
Accumulated Other Comprehensive Income | 297K | 36K | (192K) | (975K) | 24K | 25.2K | |
Property Plant Equipment | 3.2M | 9.2M | 66.3M | 61.6M | 70.8M | 74.4M | |
Other Liab | 2.9M | 5.2M | 7.0M | 9.1M | 10.4M | 11.0M | |
Net Tangible Assets | 696.6M | 625.9M | 540.9M | 400.4M | 460.5M | 403.1M | |
Retained Earnings Total Equity | (1.5B) | (1.7B) | (2.0B) | (2.2B) | (1.9B) | (1.8B) | |
Capital Surpluse | 1.9B | 2.4B | 2.6B | 2.7B | 3.1B | 1.6B | |
Inventory | 6.3M | 9.7M | 7.9M | 6.6M | 35.8M | 37.6M | |
Intangible Assets | 4.1M | 2.6M | 1.1M | 65.5M | 75.3M | 79.1M | |
Net Receivables | 37.9M | 50.3M | 65.3M | 63.1M | 102.4M | 107.5M | |
Non Current Liabilities Other | 9.2M | 49.6M | 7.0M | 9.1M | 15.1M | 12.7M | |
Net Invested Capital | 699.1M | 627.0M | 540.9M | 400.4M | 431.8M | 401.6M | |
Net Working Capital | 685.4M | 611.6M | 521.8M | 382.3M | 361.9M | 383.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GM | General Motors | |
CRM | Salesforce |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 4.949 | Quarterly Revenue Growth 0.738 | Return On Assets (0) | Return On Equity (0) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.